• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
GSK to Measure Minimal Residual Disease with clonoSEQ, Adaptive Biotechnologies’ next-generation sequencing assay

GSK to Measure Minimal Residual Disease with clonoSEQ, Adaptive Biotechnologies’ next-generation sequencing assay

by MM360 Staff | Nov 11, 2020 | Featured News, Myeloma News

GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately...
ALLO-715 Phase 1 Data in Relapsed/Refractory Multiple Myeloma to be Presented at ASH

ALLO-715 Phase 1 Data in Relapsed/Refractory Multiple Myeloma to be Presented at ASH

by MM360 Staff | Nov 4, 2020 | Featured News, Myeloma News

Allogene Therapeutics, announced that it will present data on ALLO-715, an anti-BCMA AlloCAR T therapy at the 62nd Annual Meeting of the American Society of Hematology (ASH), taking place virtually December 5 – 8, 2020. The oral presentation will include data on...
Study Supports Use of Radiation Before CAR Therapy for Multiple Myeloma

Study Supports Use of Radiation Before CAR Therapy for Multiple Myeloma

by MM360 Staff | Oct 29, 2020 | Featured News, Myeloma News

Administering radiation therapy to multiple myeloma patients prior to the administration of CAR T cells  was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania....
Eliminating Disparities in Relapsed/Refractory Multiple Myeloma Care

Eliminating Disparities in Relapsed/Refractory Multiple Myeloma Care

by MM360 Staff | Oct 22, 2020 | CME

Broadcast Date: Thursday, Oct 29, 2020 at 2:00 PM Eastern (11:00 AM Pacific) Despite expanding treatment options for relapsed/refractory multiple myeloma (MM), hematology/oncology teams face persistent barriers to the delivery of quality care across MM patient...
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics

Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics

by MM360 Staff | Oct 14, 2020 | Featured News, Myeloma News

Cytovia Therapeutics has entered a research and licensing agreement with Inserm, the French National Institute of Health and Medical Research, to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma....
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT